Conjoint Associate Professor Stephen Oakley
Conjoint Associate Professor
School of Medicine and Public Health
- Email:stephen.oakley@newcastle.edu.au
- Phone:+61 2 49 223 500
Career Summary
Biography
Dr Oakley is a graduate of UNSW Medical School, Fellow of the Royal Australasian College of Physicians and a member of the Australian Rheumatology Association and the American College of Rheumatology. His doctoral thesis evaluated arthroscopic, biomechanical and histological assessments of articular cartilage in an animal model of osteoarthritis. He is presently conducting research exploring the role of connective tissue biomechanical properties in the pathogenesis of rheumatoid arthritis.
Qualifications
- PhD (Medicine), University of New South Wales
- Bachelor of Medicine, Bachelor of Surgery, University of New South Wales
- Graduate Diploma in Clinical Epidemiology, University of Newcastle
Keywords
- Cardiovascular Disease
- Rheumatoid Arthritis
- Rheumatology
Languages
- English (Mother)
Fields of Research
Code | Description | Percentage |
---|---|---|
320223 | Rheumatology and arthritis | 100 |
Professional Experience
Academic appointment
Dates | Title | Organisation / Department |
---|---|---|
1/5/2009 - |
Conjoint Associate Professor Research and teaching in the field of Rheumatology. |
University of Newcastle - Faculty of Health and Medicine, School of Medicine and Public Health Australia |
1/9/2004 - 1/4/2008 | Honorary Senior Lecturer | Kings College, University of London, UK United Kingdom |
Membership
Dates | Title | Organisation / Department |
---|---|---|
20/5/2004 - | American College of Rheumatology - International Member | American College of Rheumatology United States |
1/1/1999 - | Fellow of the Royal Australasian College of Physicians | Royal Australasian College of Physicians |
1/1/1999 - | Australian Rheumatology Association - Member | Australian Rheumatology Association Australia |
Professional appointment
Dates | Title | Organisation / Department |
---|---|---|
1/5/2008 - | Staff Specialist Rheumatologist | Hunter New England Local Health District Rheumatology Department, Division of Medicine |
1/9/2004 - 1/4/2008 | Consultant Rheumatologist | Guy's & St Thomas's NHS Foundation Trust National Health Service, United Kingdom Australia |
Awards
Prize
Year | Award |
---|---|
2002 |
ARA - Young Investigator of the Year Australian Rheumatology Association |
1998 |
Best Clinical Teacher in the Category of Registrar / Resident St George Clinical School - UNSW |
Scholarship
Year | Award |
---|---|
2000 |
NSW Branches Scholarship Arthritis Australia |
1999 |
NSW Branches Scholarship Arthritis Australia |
1998 |
Frank Spurway Scholarship Arthritis Australia |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (22 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2022 |
Koller-Smith L, Oakley S, 'Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis', RHEUMATOLOGY, 61 E146-E147 (2022)
|
||||||||||
2022 |
Giles T, Roy SP, Chandrasoma D, Oakley S, Lynnhtun K, Draganic B, 'Life-threatening gastrointestinal haemorrhage requiring surgical resection caused by SARS-CoV-2 induced ANCA associated vasculitis: A case report', INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 98 (2022)
|
||||||||||
2019 |
Jo SJ, Foley P, Oakley SP, Zhang J, Zheng M, Shin K, et al., 'Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and China', International Journal of Rheumatic Diseases, 22 1512-1520 (2019) [C1] Objectives: To conduct initial assessment of the early arthritis for psoriatic patients (EARP) questionnaire for Australian, Korean and Chinese populations using translated and li... [more] Objectives: To conduct initial assessment of the early arthritis for psoriatic patients (EARP) questionnaire for Australian, Korean and Chinese populations using translated and linguistically validated versions. To measure the proportion of patients with psoriatic arthritis (PsA) among patients with psoriasis who attended dermatology clinics. Methods: Questionnaires were translated and culturally validated into Australian English, Korean and Chinese. A multicenter, observational, descriptive estimate of the proportion of patients with PsA among patients with psoriasis attending dermatology clinics in Australia, Korea and China was conducted. Initial assessments included evaluations of floor and ceiling effects, internal consistency (using Cronbach's alpha), test-retest reliability (using intraclass coefficient), and correlations between EARP score and rheumatology findings. If the initial EARP score was =3, patients were assessed by a rheumatologist for PsA within 3¿months of their retest questionnaire. Results: Two hundred and fifty patients participated. Translated EARP questionnaires showed satisfactory internal consistency and test-retest reliability. A potential floor effect was observed for the Chinese and Korean versions. Cronbach's alpha was 0.885 (Australian), 0.776 (Korean) and 0.789 (Chinese), indicating acceptable internal consistency. Intraclass correlation coefficients were 0.89 (Australian), 0.86 (Korean) and 0.87 (Chinese), indicating acceptable test-retest reliability. EARP summary scores had weak to moderate linear correlation with the relevant PsA assessments. Overall, 32 (12.8%) patients were diagnosed with PsA based on Classification for Psoriatic Arthritis (CASPAR) score. Conclusion: The Australian, Korean, and Chinese versions of the EARP questionnaire are suitable for the early detection of PsA symptoms in patients with psoriasis by dermatologists working in specialist dermatology clinics. Trial registration: NCT02470481.
|
Nova | |||||||||
2018 |
Davis JS, Young M, Lennox S, Jones T, Piera K, Pickles R, Oakley S, 'The effect of curing hepatitis C with direct-acting antiviral treatment on endothelial function', Antiviral Therapy, 23 687-694 (2018) [C1] Background: Epidemiological data suggest that chronic HCV infection (CHC) is associated with increased cardiovascular risk, but it is unknown if it is associated with endothelial ... [more] Background: Epidemiological data suggest that chronic HCV infection (CHC) is associated with increased cardiovascular risk, but it is unknown if it is associated with endothelial dysfunction. We aimed to assess the effect of antiviral treatment on endothelial function in non-cirrhotic adults with CHC. Methods: Self-controlled before and after study. All patients had genotype-1 CHC and were treated with 12 weeks of paritaprevir/ritonavir, ombitasvir and dasabuvir (PrOD), with ribavirin added for those with genotype-1a infection. Endothelial function was assessed at three time points before antiviral treatment, at treatment weeks 1, 4, 8 and 12, and 12 weeks after the end of treatment. The main assessment tools were reactive hyperaemia peripheral arterial tonometry (RHPAT) and serum concentrations of angiopoietin-2 (Ang-2) and E-selectin. Results: A total of 16 patients were enrolled. Mean (SD) age was 51.4 (6.9) years and 11 participants (69%) were male. All 16 patients achieved a sustained virological response. The mean (SD) baseline RHPAT index was 2.05 (0.48), and there was no significant change during treatment (mean within-patient change from baseline to end of treatment =-0.23 [0.45]; P= not significant). There was a significant improvement in both mean Ang-2 (baseline 2.44 [0.79] ng/ml, within-patient change -0.60 [0.44]; P<0.001) and E-selectin (baseline 48.7 [21.5] ng/ml, within-patient change -14.4 [13.0]; P<0.001). Conclusions: Removing HCV viraemia is associated with a significant improvement in endothelial function as measured by serum markers, but not in bedside microvascular reactivity. Chronic HCV viraemia may be associated with endothelial cell dysfunction and therefore long-term cardiovascular risk.
|
Nova | |||||||||
Show 19 more journal articles |
Conference (47 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2024 | Meester JJ, Hebert A, Bastiaansen M, Rabaut L, Bastianen J, Boeckx N, et al., 'Expanding genotype-phenotype associations in biglycan-related Meester-Loeys syndrome', EUROPEAN JOURNAL OF HUMAN GENETICS, SCOTLAND, Glasgow (2024) | ||||
2023 | Oakley S, Gill K, 'EVALUATION OF THE CONSTRUCT OF CONSTITUTIONAL STIFFNESS IN ANTI-CCP-ANTIBODY-POSITIVE RHEUMATOID ARTHRITIS AND CONTROLS (V2)', INTERNAL MEDICINE JOURNAL (2023) | ||||
2023 | Oakley S, Stott S, Gill K, 'BIOMECHANICAL CORRELATES OF ARTICULAR DAMAGE IN ANTICCP ANTIBODY POSITIVE RHEUMATOID ARTHRITIS', INTERNAL MEDICINE JOURNAL (2023) | ||||
2016 | Oakley S, Major G, Mathers D, van der Kallen J, Collins M, Toh M, et al., 'A Randomised Controlled Trial Evaluating the Effect of Adalimumab upon Biomarkers of Cardiovascular Risk in ACPA-Positive Rheumatoid Arthritis', ARTHRITIS & RHEUMATOLOGY, DC, Washington (2016) | ||||
2014 | Oakley S, Esmaili N, Major G, Mathers D, Ratnarajah S, Van der Kallen J, et al., 'ENDOTHELIAL FUNCTION IS MOST STRONGLY INFLUENCED BY LIPID PROFILE AND DISEASE ACTIVITY IN ACPA-POSITIVE RHEUMATOID ARTHRITIS', INTERNAL MEDICINE JOURNAL (2014) [E3] | Nova | |||
2014 |
Oakley S, Esmaili N, Major G, Mathers D, Ratnarajah S, van der Kallen J, et al., 'A Randomised Controlled Trial Evaluating the Effect of Humira upon Endothelial Function in ACPA Positive Rheumatoid Arthritis - an Interim Analysis', ARTHRITIS & RHEUMATOLOGY, MA, Boston (2014) [E3]
|
||||
Show 44 more conferences |
Thesis / Dissertation (1 outputs)
Year | Citation | Altmetrics | Link |
---|---|---|---|
2004 | Oakley SP, Arthroscopic assessment of articular cartilage in an animal model of osteoarthritis, Faculty of Medicine, University of New South Wales (2004) |
Grants and Funding
Summary
Number of grants | 3 |
---|---|
Total funding | $241,000 |
Click on a grant title below to expand the full details for that specific grant.
20162 grants / $80,000
Humira and Endothelial Function in Rheumatoid Arthritis - 2 (HEART-RA-2)$50,000
Hunter Heart RA-2 had several parts:
1. RCT evaluating the effect of adalimumb upon cardiovascular biomarkers in ACPA-negative RA. This was terminated early due to recruitment challenges.
2. Evaluation of cardiovascular biomarkers in Pre-RA (ACPA-Positive individuals without RA) and First degree relatives of people with ACPA-positive RA. This was terminated early due to recruitment challenges.
3. Evaluation of cardiovascular biomarker assessments and HLA-DR4 ("Shared Epitope") status in Healthy Volunteers. This section was completed with 47 recruits. The analysis found no significant results. Participants in this study were then invited to participate in the T-BIRD study.
Funding body: Abbvie Pharmaceuticals
Funding body | Abbvie Pharmaceuticals |
---|---|
Project Team | Stephen Oakley, Zsolt Balogh, Paul Mansfield, Gabor Major, David Mathers, John van der Kallen, Mark Collins, Marc Toh, John Glass, Aishwarya Suhkdeo |
Scheme | Abbvie Investigator-Initiated Grant |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | Aust Competitive - Non Commonwealth |
Category | 1NS |
UON | N |
31P1H flexible surface coil for Siemens Prisma, Software version VE11B/C* coil for MRI$30,000
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Laureate Professor Roger Smith, Associate Professor Saadallah Ramadan, Professor Ronald Plotnikoff, Conjoint Associate Professor Stephen Oakley, Doctor Peter Lau, Doctor Christian Abel |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2016 |
Funding Finish | 2016 |
GNo | G1601315 |
Type Of Funding | C2200 - Aust Commonwealth – Other |
Category | 2200 |
UON | Y |
20131 grants / $161,000
Humira and Endothelial Function in Rheumatoid Arthritis (HEART - RA)$161,000
Rheumatoid Arthritis (RA) is a severe immune-mediated destructive inflammatory arthritis that affects the peripheral joints and affects 1% of the population. It is also associated with double the risk of cardiovascular disease and reduces life expectancy by 10-15 years. This effect is particularly pronounced in the anti-CCP antibody (ACPA) positive sub-group. Recent advances in the therapeutics of RA have greatly improved the treatment of arthritis. However, the mechanisms of cardiovascular disease in RA are not fully understood and it is not known if these new treatments also reduce the risk of cardiovascular disease.
Hunter HEART-RA is a single-site randomised controlled trial of 60 patients with ACPA-positive RA being conducted through the Department of Rheumatology, John Hunter Hospital. The study will determine whether the drug adalimumab influences cardiovascular risk in patients with RA using a platform of cardiovascular biomarkers including endothelial function, central arterial pressure indices and aortic stiffness. The study will also explore a range of potential mechanisms of cardiovascular disease including genetic risk, lipid profiling and novel neutrophil-mediated mechanisms of immunity.
Recruitment for the study commenced in 2013. The final participant was recruited mid 2015. The study will conclude with final analysis in 2016.
Funding body: Abbvie Pharmaceuticals
Funding body | Abbvie Pharmaceuticals |
---|---|
Project Team | Stephen Oakley |
Scheme | Abbvie Investigator-Initiated Grant |
Role | Lead |
Funding Start | 2013 |
Funding Finish | 2016 |
GNo | |
Type Of Funding | Aust Competitive - Non Commonwealth |
Category | 1NS |
UON | N |
Research Projects
T-BIRD: Tissue Biomechanics and the Inflammatory Rheumatic Diseases 2016 - 2019
Humira and Endothelial Function in Rheumatoid Arthritis (HEART-RA) 2013 -
Rheumatoid Arthritis (RA) is a severe immune-mediated destructive inflammatory arthritis that affects the peripheral joints and affects 1% of the population. It is also associated with double the risk of cardiovascular disease and reduces life expectancy by 10-15 years. This effect is particularly pronounced in the anti-CCP antibody (ACPA) positive sub-group. Recent advances in the therapeutics of RA have greatly improved the treatment of arthritis. However, the mechanisms of cardiovascular disease in RA are not fully understood and it is not known if these new treatments also reduce the risk of cardiovascular disease.
Hunter HEART-RA is a single-site randomised controlled trial of 60 patients with ACPA-positive RA being conducted through the Department of Rheumatology, John Hunter Hospital. The study will determine whether the drug adalimumab influences cardiovascular risk in patients with RA using a platform of cardiovascular biomarkers including endothelial function, central arterial pressure indices and aortic stiffness. The study will also explore a range of potential mechanisms of cardiovascular disease including genetic risk, lipid profiling and novel neutrophil-mediated mechanisms of immunity.
Recruitment for the study commenced in 2013. The final participant was recruited mid 2015. The study will conclude with final analysis in 2016.
Grants
Humira and Endothelial Function in Rheumatoid Arthritis (HEART - RA)
Funding body: Abbvie Pharmaceuticals
Funding body | Abbvie Pharmaceuticals |
---|---|
Description | Rheumatoid Arthritis (RA) is a severe immune-mediated destructive inflammatory arthritis that affects the peripheral joints and affects 1% of the population. It is also associated with double the risk of cardiovascular disease and reduces life expectancy by 10-15 years. This effect is particularly pronounced in the anti-CCP antibody (ACPA) positive sub-group. Recent advances in the therapeutics of RA have greatly improved the treatment of arthritis. However, the mechanisms of cardiovascular disease in RA are not fully understood and it is not known if these new treatments also reduce the risk of cardiovascular disease. Hunter HEART-RA is a single-site randomised controlled trial of 60 patients with ACPA-positive RA being conducted through the Department of Rheumatology, John Hunter Hospital. The study will determine whether the drug adalimumab influences cardiovascular risk in patients with RA using a platform of cardiovascular biomarkers including endothelial function, central arterial pressure indices and aortic stiffness. The study will also explore a range of potential mechanisms of cardiovascular disease including genetic risk, lipid profiling and novel neutrophil-mediated mechanisms of immunity. Recruitment for the study commenced in 2013. The final participant was recruited mid 2015. The study will conclude with final analysis in 2016. |
Scheme | Abbvie Investigator-Initiated Grant |
Edit
Research Collaborations
The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.
Country | Count of Publications | |
---|---|---|
Australia | 30 | |
United Kingdom | 16 | |
Belgium | 2 | |
China | 1 | |
Finland | 1 | |
More... |
Conjoint Associate Professor Stephen Oakley
Position
Conjoint Associate Professor
School of Medicine and Public Health
College of Health, Medicine and Wellbeing
Contact Details
stephen.oakley@newcastle.edu.au | |
Phone | +61 2 49 223 500 |
Fax | +61-249-245-712 |
Office
Room | Rheumatology Department |
---|---|
Building | John Hunter Hospital |
Location | New Lambton , |